Share Incentive Plan - The company granted a total of 12,096,900 shares under the share incentive plan on November 13, 2023, which will not result in the issuance of new shares[2] - A total of 169,605,750 shares are available for grant under the share incentive plan, representing 9.33% of the company's issued shares as of the 2023 annual report date[4] - The share incentive plan aims to align the interests of the company's directors and employees with those of shareholders[2] - The share incentive plan allows for a maximum of 10% of the issued shares to be granted, equating to 181,702,650 shares[2] - The total number of shares granted to the five highest-paid individuals amounted to 1,618,800 shares[2] - The vesting period for the granted shares is from November 13, 2024, to November 13, 2026[2] Share Valuation - The fair value of the granted shares on the date of award was HKD 7.45 per share, with the closing prices being HKD 7.77 and HKD 7.45 on the respective dates[3] - The company did not purchase any incentive shares during the fiscal year ending December 31, 2023[3] Corporate Governance - The company’s board of directors includes six executive directors and three independent non-executive directors[5] - The announcement does not affect other information contained in the 2023 annual report, which remains accurate and unchanged[4]
联邦制药(03933) - 2024 - 年度业绩